Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Ovulation Induction”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,693 records · Page 94Linked to original sources
PubMed1990

[Induction of ovulation, with pulsatile GnRH by subcutaneous route in amenorrhea of hypothalamic origin].

Twelve patients affected by secondary amenorrhea of hypothalamic origin, resistant to Clomiphene Citrate treatment, were treated for 2 consecutive cycles with subcutaneous pulsatile administration (s.c.) of Gn-RH by computerized portable pump (Ziklomat-Ferring) at a dose of 20 mcg every 60-90 minutes for a total of 20 cycles. On the average 85% of ovulatory cycles and 30% of pregnancies per cycle were obtained with this therapy. The number of ovulatory cycles and pregnancies obtained in the second cycle of treatment were in percentage higher, with respect to the first cycle of treatment. Only one subject, not responsive to both cycles of s.c. administration, underwent an intravenous therapy with positive results.

Adult↗
PubMed1988

[Structural and functional indices of disturbances of oocyte maturation in androgenized rats after induction of ovulation with pregnant mare's serum and luliberin].

The ultrastructure of oocytes from large follicles and the meiotic maturation rate of preovulatory oocytes of intact and androgenized rats were studied. The oocytes of defeminized animals were characterized by the lack of organelles and by changes of their structure. According to the rate of meiosis they were divided into two groups. The one entered the II stage metaphase earlier than in the control, the other was characterized by a slower chromosome transformation.

Androgens↗
PubMed1988

[Ovarian response and induction of ovulation with human menopausal gonadotropin of different ratio of FSH to LH content in women with ovarian insufficiency].

Human menopausal gonadotropin (hMG) with different ratios of FSH to LH content (FSH: LH = 1.2:1 (GNR 1.2), FSH:LH = 1.6:1 (GNR 1.6), FSH:LH = 3:1 (GNR 3) in biological activity, respectively) was used in this study to examine the effects of these hMGs on ovary, and subsequent follicular maturation and ovulation. In 5 women, 300 IU of hMG (GNR 1.2, GNR 1.6 and GNR 3) was injected in turns during different midfollicular phases of the cycle (day 5-day 9) and serum estradiol (E2) was measured at 0, 24 hrs, 48 hrs, 72 hrs after injection to assess ovarian response to different hMG. Serum E2 response at 24 hrs, 48 hrs, 72 hrs after injection of hMG compared to the preinjected E2 level were 2.2, 1.8, and 1.5 fold with GNR 1.2; 2.6, 2.4 and 1.9 fold with GNR 1.6; and 2.2, 2.4 and 2.3 fold with GNR 3, respectively. These hMGs were administered in turns to women who were suffering from amenorrhea (6 cases), anovulatory (8 cases) and luteal phase dysfunction (10 cases) for treatment of ovarian dysfunction. The mean doses of hMG per cycle required to induce ovulation were 1,125 IU with GNR 1.2, 1,050 IU with GNR 1.6 and 925 IU with GNR 3 in these 24 women. The success rates for ovulation with GNR 1.2, GNR 1.6 and GNR 3 were 70.8, 79.2 and 87.5%. The appearance rates for ovarian hyperstimulation syndrome (OHSS) with GNR 1.2, GNR 1.6, and GNR 3 were 4.2, 8.3 and 8.3%, respectively. These results infer that a different ratio of FSH to LH in hMG has an effect on follicular maturation and ovulation, and that the increase in the rate of ovulation and prevention of OHSS may accompany the regulating of this ratio, and that hMG with a higher FSH content (ratio of FSH to LH is more than three) should be studied further as a promising agent to use in inducing ovulation in women.

Estradiol↗